Literature DB >> 21336775

Optimization of glioblastoma multiforme stem cell isolation, transfection, and transduction.

Demirkan B Gürsel1, Robel T Beyene, Christoph Hofstetter, Jeffry P Greenfield, Mark M Souweidane, Michael Kaplitt, Margarita Arango-Lievano, Brian Howard, John A Boockvar.   

Abstract

It has been postulated that brain tumor stem cells (TSCs) may be the population of cells responsible for the maintenance and recurrence of glioblastoma multiforme (GBM). The purpose of this study was to optimize a reproducible protocol for generating TSCs for their subsequent transfection or transduction. Patient GBMs were enzymatically and mechanically dissociated and tumor spheres were resuspended in appropriate media and analyzed to ensure they met stem cell criteria. These cells were then transfected with a plasmid or transduced with a viral vector to introduce a previously absent gene and then allowed to form tumor spheres. Tumor spheres were generated from patient GBMs without contamination. These cells met stringent criteria as stem cells, including multipotentiality and self-renewal. High efficiency transfection and transduction of tumor spheres was possible, even at the core of the sphere. This allowed for the introduction of new genes to the TSCs, as evidenced by fluorescent microscopy and Western blot analysis. This study is a guide to optimize the generation of patient derived GBM tumor spheres without RBC and dead cell contamination. GBM TSCs within tumor spheres can easily be transfected with plasmids or transduced with a virus. This is important from a therapeutic perspective if gene replacement is to be successful in replacing genes lost in GBM progression or to knock down or silence genes that are over-expressed in malignant brain tumors.

Entities:  

Mesh:

Year:  2011        PMID: 21336775     DOI: 10.1007/s11060-011-0528-2

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  33 in total

1.  Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells.

Authors:  Michael F Clarke; John E Dick; Peter B Dirks; Connie J Eaves; Catriona H M Jamieson; D Leanne Jones; Jane Visvader; Irving L Weissman; Geoffrey M Wahl
Journal:  Cancer Res       Date:  2006-09-21       Impact factor: 12.701

Review 2.  Tumor heterogeneity.

Authors:  G H Heppner
Journal:  Cancer Res       Date:  1984-06       Impact factor: 12.701

3.  EGFR signaling is differentially activated in patient-derived glioblastoma stem cells.

Authors:  Brian M Howard; Demirkan B Gursel; Anne-Marie Bleau; Robel T Beyene; Eric C Holland; John A Boockvar
Journal:  J Exp Ther Oncol       Date:  2010

4.  Glioblastoma-derived tumorospheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype.

Authors:  Andrea Salmaggi; Amerigo Boiardi; Maurizio Gelati; Annamaria Russo; Chiara Calatozzolo; Emilio Ciusani; Francesca Luisa Sciacca; Arianna Ottolina; Eugenio Agostino Parati; Caterina La Porta; Giulio Alessandri; Carlo Marras; Danilo Croci; Marco De Rossi
Journal:  Glia       Date:  2006-12       Impact factor: 7.452

5.  Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens.

Authors:  Steven M Pollard; Koichi Yoshikawa; Ian D Clarke; Davide Danovi; Stefan Stricker; Roslin Russell; Jane Bayani; Renee Head; Marco Lee; Mark Bernstein; Jeremy A Squire; Austin Smith; Peter Dirks
Journal:  Cell Stem Cell       Date:  2009-06-05       Impact factor: 24.633

6.  Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.

Authors:  Hiroaki Wakimoto; Santosh Kesari; Christopher J Farrell; William T Curry; Cecile Zaupa; Manish Aghi; Toshihiko Kuroda; Anat Stemmer-Rachamimov; Khalid Shah; Ta-Chiang Liu; Deva S Jeyaretna; Jason Debasitis; Jan Pruszak; Robert L Martuza; Samuel D Rabkin
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

7.  Evaluating therapeutic efficacy against cancer stem cells: new challenges posed by a new paradigm.

Authors:  Jean C Y Wang
Journal:  Cell Stem Cell       Date:  2007-11       Impact factor: 24.633

Review 8.  The culture of neural stem cells.

Authors:  Sohail Ahmed
Journal:  J Cell Biochem       Date:  2009-01-01       Impact factor: 4.429

9.  Cancerous stem cells can arise from pediatric brain tumors.

Authors:  Houman D Hemmati; Ichiro Nakano; Jorge A Lazareff; Michael Masterman-Smith; Daniel H Geschwind; Marianne Bronner-Fraser; Harley I Kornblum
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-26       Impact factor: 11.205

10.  Cryopreservation of neurospheres derived from human glioblastoma multiforme.

Authors:  Yuk-Kien Chong; Tan-Boon Toh; Norazean Zaiden; Anuradha Poonepalli; Siew Hong Leong; Catherine Ee Ling Ong; Yiting Yu; Patrick B Tan; Siew-Ju See; Wai-Hoe Ng; Ivan Ng; Manoor P Hande; Oi Lian Kon; Beng-Ti Ang; Carol Tang
Journal:  Stem Cells       Date:  2009-01       Impact factor: 6.277

View more
  12 in total

Review 1.  The roles of viruses in brain tumor initiation and oncomodulation.

Authors:  Alexander Kofman; Lucasz Marcinkiewicz; Evan Dupart; Anton Lyshchev; Boris Martynov; Anatolii Ryndin; Elena Kotelevskaya; Jay Brown; David Schiff; Roger Abounader
Journal:  J Neurooncol       Date:  2011-07-01       Impact factor: 4.130

2.  Tight regulation between cell survival and programmed cell death in GBM stem-like cells by EGFR/GSK3b/PP2A signaling.

Authors:  Demirkan B Gürsel; Matei A Banu; Nicholas Berry; Roberta Marongiu; Jan-Karl Burkhardt; Keith Kobylarz; Michael G Kaplitt; Shahin Rafii; John A Boockvar
Journal:  J Neurooncol       Date:  2014-10-26       Impact factor: 4.130

Review 3.  Glioblastoma cancer stem-like cells: implications for pathogenesis and treatment.

Authors:  Edjah Kweku-Ebura Nduom; Costas George Hadjipanayis; Erwin G Van Meir
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

4.  The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response.

Authors:  Quintino Giorgio D'Alessandris; Mauro Biffoni; Maurizio Martini; Daniele Runci; Mariachiara Buccarelli; Tonia Cenci; Michele Signore; Louis Stancato; Alessandro Olivi; Ruggero De Maria; Luigi M Larocca; Lucia Ricci-Vitiani; Roberto Pallini
Journal:  Neuro Oncol       Date:  2017-08-01       Impact factor: 12.300

5.  Protein phosphatase 2A mediates dormancy of glioblastoma multiforme-derived tumor stem-like cells during hypoxia.

Authors:  Christoph P Hofstetter; Jan-Karl Burkhardt; Benjamin J Shin; Demirkan B Gürsel; Lynn Mubita; Ramana Gorrepati; Cameron Brennan; Eric C Holland; John A Boockvar
Journal:  PLoS One       Date:  2012-01-11       Impact factor: 3.240

6.  Glioblastoma stem-like cells-biology and therapeutic implications.

Authors:  Demirkan B Gürsel; Benjamin J Shin; Jan-Karl Burkhardt; Kartik Kesavabhotla; Cody D Schlaff; John A Boockvar
Journal:  Cancers (Basel)       Date:  2011-06-10       Impact factor: 6.639

7.  Innovative Therapies against Human Glioblastoma Multiforme.

Authors:  Annamaria Cimini; Rodolfo Ippoliti
Journal:  ISRN Oncol       Date:  2011-07-24

8.  Isolation, cultivation and identification of brain glioma stem cells by magnetic bead sorting.

Authors:  Xiuping Zhou; Chao Zheng; Qiong Shi; Xiang Li; Zhigang Shen; Rutong Yu
Journal:  Neural Regen Res       Date:  2012-05-05       Impact factor: 5.135

Review 9.  Bringing the heavy: carbon ion therapy in the radiobiological and clinical context.

Authors:  Cody D Schlaff; Andra Krauze; Arnaud Belard; John J O'Connell; Kevin A Camphausen
Journal:  Radiat Oncol       Date:  2014-03-28       Impact factor: 3.481

10.  MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells.

Authors:  Kaushal Joshi; Yeshavanth Banasavadi-Siddegowda; Xiaokui Mo; Sung-Hak Kim; Ping Mao; Cenk Kig; Diana Nardini; Robert W Sobol; Lionel M L Chow; Harley I Kornblum; Ronald Waclaw; Monique Beullens; Ichiro Nakano
Journal:  Stem Cells       Date:  2013-06       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.